摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-3-甲基-5-氟吡啶 | 38186-84-4

中文名称
2-氯-3-甲基-5-氟吡啶
中文别名
2-氯-5-氟-3-甲基吡啶
英文名称
2-chloro-5-fluoro-3-methylpyridine
英文别名
——
2-氯-3-甲基-5-氟吡啶化学式
CAS
38186-84-4
化学式
C6H5ClFN
mdl
MFCD04972725
分子量
145.564
InChiKey
FMPYGEFGXUAAKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    41.0 to 45.0 °C
  • 沸点:
    177.9±35.0 °C(Predicted)
  • 密度:
    1.264±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    2-8°C

SDS

SDS:a2ebb419fb968ff34615194a69bc9624
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Chloro-5-fluoro-3-methylpyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-5-fluoro-3-methylpyridine
CAS number: 38186-84-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5ClFN
Molecular weight: 145.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    2-氯-3-甲基-5-氟吡啶 在 [(2-di-tert-butylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl)-2-(2’-amino-1,1‘-biphenyl)]palladium(II) methanesulfonate 、 caesium carbonate溶剂黄146lithium diisopropyl amide 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 11.0h, 生成 methyl (R)-3-((1R,3R)-1-(2-(2-((tert-butoxycarbonyl)(3-fluoropropyl)amino)ethoxy)-5-fluoro-3-methylpyridin-4-yl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropanoate
    参考文献:
    名称:
    [EN] ESTROGEN RECEPTOR MODULATORS
    [FR] MODULATEURS DU RÉCEPTEUR DES ŒSTROGÈNES
    摘要:
    该规范涉及到式(I)的化合物,以及其药用盐,用于其制备的工艺和中间体,含有它们的药物组合物,以及它们在治疗细胞增殖性疾病中的用途。
    公开号:
    WO2018138303A1
  • 作为产物:
    描述:
    5-氨基-2-氯-3-甲基吡啶 在 hexafluorophosphoric acid 作用下, 生成 2-氯-3-甲基-5-氟吡啶
    参考文献:
    名称:
    Non-basic histamine H1-antagonists. I. Synthesis and biological evaluation of some substituted 2-(2-pyridylaminoalkylamino) pyrimidones and related compounds
    摘要:
    DOI:
    10.1016/0223-5234(89)90006-8
点击查看最新优质反应信息

文献信息

  • [EN] NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR DE SOMATOSTATINE DE SOUS-TYPE 4 (SSTR4)
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014184275A1
    公开(公告)日:2014-11-20
    The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    这项发明涉及一般式(I)的3-aza-双环[3.1.0]己烷-6-羧酸酰胺衍生物,它们是生长抑素受体亚型4(SSTR4)的激动剂,用于预防或治疗与SSTR4相关的医学疾病。此外,该发明涉及制备药物组合物的方法,以及根据该发明制备化合物的方法。
  • [EN] OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] DÉRIVÉS D'OXAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
    申请人:NOVARTIS AG
    公开号:WO2012095463A1
    公开(公告)日:2012-07-19
    The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.
    本发明涉及式(I)的新杂环化合物,其中所有变量如说明书中所定义,以自由形式或药物可接受的盐形式存在,以及它们的制备、医学用途和包含它们的药物。
  • [EN] PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE POUVANT ÊTRE UTILISÉS EN TANT QU'AGONISTES DE L'OREXINE
    申请人:GLAXO GROUP LTD
    公开号:WO2010072722A1
    公开(公告)日:2010-07-01
    This invention relates to imidazopyridylmethylene substituted piperidine derivatives orexin antagonists and their use as pharmaceuticals.
    这项发明涉及咪唑吡啶甲基取代哌啶衍生物促睡素拮抗剂及其作为药物的用途。
  • [EN] GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE GLYCOSIDASES
    申请人:ASCENEURON SA
    公开号:WO2016030443A1
    公开(公告)日:2016-03-03
    Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    式(I)中A、R、W、Q、n和m的含义如权利要求所述,可用于治疗tau病和阿尔茨海默病。
  • WDR5 INHIBITORS AND MODULATORS
    申请人:Vanderbilt University
    公开号:US20200102288A1
    公开(公告)日:2020-04-02
    Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    描述了抑制WDR5和相关蛋白质-蛋白质相互作用的亚氨基-氮杂环-苯甲酰胺化合物,包括这些化合物的药物组合物,以及使用这些化合物和组合物治疗受试者疾病和状况的方法。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-